Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Madrigal Pharmaceuticals Inc (MDGL)

Madrigal Pharmaceuticals Inc (MDGL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Madrigal Pharmaceuticals Inc 200 BARR HARBOR DRIVE SUITE 200 WEST CONSHOHOCKEN PA 19428 USA

www.madrigalpharma.com Employees: 915 P: 267-824-2827

Sector:

Medical

Description:

Madrigal Pharmaceuticals, Inc. is engaged in developing small-molecule drugs addressing cardiovascular and metabolic diseases. Its products pipeline include MGL-3196, an orally administered liver-directed thyroid hormone receptor-' agonist that is used for the treatment of NASH, dyslipidemia/hypercholesterolemia and high triglycerides; and MGL-3745, a thyroid hormone receptor-' agonist which are in pre-clinical trial stage. Madrigal Pharmaceuticals Inc., formerly known as Synta Pharmaceuticals Corp., is based in Fort Washington, Pennsylvania.

Key Statistics

Overview:

Market Capitalization, $K 10,078,460
Enterprise Value, $K 10,214,560
Shares Outstanding, K 22,940
Float, K 18,008
% Float 78.50%
Short Interest, K 3,619
Short Float 15.78%
Days to Cover 11.08
Short Volume Ratio 0.78
% of Insider Shareholders 21.50%
% of Institutional Shareholders 98.50%

Financials:

Annual Sales, $ 958,400 K
Annual Net Income, $ -288,280 K
Last Quarter Sales, $ 321,080 K
Last Quarter Net Income, $ -58,570 K
EBIT, $ -300,100 K
EBITDA, $ -293,780 K

Growth:

1-Year Return 30.77%
3-Year Return 81.82%
5-Year Return 272.83%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 1.83%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -2.57 on 02/19/26
Next Earnings Date 05/07/26
Earnings Per Share ttm -12.87
EPS Growth vs. Prev Qtr 49.41%
EPS Growth vs. Prev Year 5.17%
Annual Dividend & Yield (Paid) 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%
Most Recent Split 1-35 on 07/25/16

MDGL Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -43.76%
Return-on-Assets % -24.88%
Profit Margin % -30.08%
Debt/Equity 0.56
Price/Sales 10.41
Price/Cash Flow N/A
Price/Book 16.39
Book Value/Share 26.54
Interest Coverage -11.92
60-Month Beta -0.97
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar